We presented a case of pityriasis rubra pilaris that developed after COVID-19 infection and treated with anti-tumor necrosis factor (adalimumab), which was not previously reported in an adult.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Coronavirus disease-2019 (COVID-19) has been associated with multiple skin lesions as well as causing common respiratory symptoms.
📊
Key Findings & Data:Coronavirus disease-2019 (COVID-19) has been associated with multiple skin lesions as well as causing common respiratory symptoms.
💡
Conclusion & Impact:We presented a case of pityriasis rubra pilaris that developed after COVID-19 infection and treated with anti-tumor necrosis factor (adalimumab), which was not previously reported in an adult.
🔬Design:Research Article
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters
Abstract
Coronavirus disease-2019 (COVID-19) has been associated with multiple skin lesions as well as causing common respiratory symptoms. We presented a case of pityriasis rubra pilaris that developed after COVID-19 infection and treated with anti-tumor necrosis factor (adalimumab), which was not previously reported in an adult.
Özet
Koronavirüs hastalığı-2019 (COVİD-19) yaygın respiratuvar semptomlara yol açmasının yanı sıra çok sayıda deri lezyonu ile ilişkilendirilmiştir. Daha önce erişkinde bildirilmemiş, COVİD-19 enfeksiyonu sonrasında gelişen ve anti-tümör nekroz faktörü (adalimumab) ile tedavi edilen pitrizis rubra pilaris olgusu sunduk.
🔖
Cite This Article
Öztürk, P., Nazik, H., Mülayim, M. K., Koçarslan, S., Kuş, M. M., Bulut, T., Akgüç, E. R. (2022). Pityriasis rubra pilaris developing after COVID-19. Türkderm Türk deri hastalıkları ve frengi arşivi, Cilt: 56 - Sayı: 1, 42–45. https://ajindex.com/articles/622433
World Health Organization: WHO announces COVID-19 outbreak a pandemic. (Published: 2020; Accessed: May 23, 2020). World Health Organization; 2020
Perna A, Passiatore M, Massaro A, et al.: Skin manifestations in COVID-19 patients, state of the art. A systematic review. Int J Dermatol 2021;60:547- 53
Klejtman T: Skin and COVID-19. J Med Vasc 2020;45:175-6
Lai CC, Ko WC, Lee PI, Jean SS, Hsueh PR: Extra-respiratory manifestations of COVID-19. Int J Antimicrob Agents 2020;56:106024
Sachdeva M, Gianotti R, Shah M, et al.: Cutaneous manifestations of COVID-19: Report of three cases and a review of literature. J Dermatol Sci 2020;98:75-81
Darlenski R, Tsankov N: COVID-19 pandemic and the skin: What should dermatologists know? Clin Dermatol 2020;38:785-7
Katsarou-Katsari A, Filippou A, Theoharides TC: Effect of stress and other psychological factors on the pathophysiology and treatment of dermatoses. Int J Immunopathol Pharmacol 1999;12:7-11
Aguilar-Gamboa FR, Cubas-Alarcon D, Villegas-Chiroque M, Failoc-Rojas VE: Pityriasis rubra pilaris post-infection due COVID-19: Case report. Colomb Med 2021;52:e7014577
Wang D, Chong VC, Chong WS, Oon HH: A review on pityriasis rubra pilaris. Am J Clin Dermatol 2018;19:377-90
Blauvelt A, Nahass GT, Pardo RJ, Kerdel FA: Pityriasis rubra pilaris and HIV infection. J Am Acad Dermatol 1991;24:703-5
Kawara S, Miyake M, Oiso N, Kawada A: Pityriasis rubra pilaris with preceding cytomegalovirus infection. Dermatology 2009;219:350-2
Wang T, Liu J, Liu Y, Zheng H: Pityriasis rubra pilaris (PRP) with preceding Epstein-Barr virus infection: A new type PRP with non-HIV virus infection? Chin Med J (Engl) 2014;127:2391.